Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâs RNAi-based therapeutics leverage this natural pathway of gene silencing. Source
No articles found.
Novocure is a global oncology company working to extend survival in some of the mo...
Novocure is a global oncology company working t...
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Alder BioPharmaceuticals is a clinical-stage bi...
Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...
Cellect Biotechnology Ltd. was founded in 2011 ...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to ...
Dermira is a biopharmaceutical company dedicate...
Join the National Investor Network and get the latest information with your interests in mind.